Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

Summary

The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.

Eligibility

Inclusion Criteria:

* CD19+ relapsed or refractory lymphoblastic leukemia/lymphoma;
* Karnofsky or Lansky performance scale greater or equal to 70;
* T-cells count in peripheral blood \>150 cells/µL;
* Written informed consent.

Exclusion Criteria:

* primary immunodeficiencies or genetic syndromes;
* neurologic diseases;
* autoimmune diseases or polyallergie;
* transfusion of donor lymphocyte less than 6 week before CAR-T cells infusion;
* GvHD grade 2-4;
* uncontrolled systemic infection;
* hypoxia (Sp02\<90%)
* severe hepatic dysfunction: ALT or AST \>=3x upper limit of normal for age;
* renal dysfunction: serum creatinine level \>=3x upper limit of normal for age;
* positive serology for human immunodeficiency virus (HIV), active hepatite C or B;
* pregnancy.

Conditions3

Interventions2

Related trials

• Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus — Beijing GoBroad Hospital
• Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE) — National University of Malaysia
• Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL — National University of Malaysia
• Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE — The Children's Hospital of Zhejiang University School of Medicine
• Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE — Chongqing Precision Biotech Co., Ltd
• Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR — University Hospital Heidelberg
• A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) — Merck Sharp & Dohme LLC
• A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus — Hoffmann-La Roche

Browse More Trials